Parmax Pharma share price
BSE: 540359Pharmaceuticals & BiotechnologySmall Cap
Parmax Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 2017
Last close ₹135.05down ₹1.35 (0.99%)
Share price at the BSE close on 26 Oct 2026. Previous close ₹136.40.
26 Oct: open ₹135.05, high ₹135.05, low ₹135.05
52-week range of traded prices to 26 Oct 2026
₹22.60Low, 25 Mar 2026₹139.10High, 5 Oct 2026
- Under BSE's graded surveillance, stage 0, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹93 Cr4,411th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −70.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 657
Results
Standalone; ₹ crore.Parmax Pharma quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −17.6%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹8.22 Crup 148.16%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- ₹2.20 CrQuarter to Mar 2026: −₹0.58 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 26.8%
Revenue by quarter
Peak revenue ₹9.28 Cr, quarter to Sep 2024; lowest ₹1.94 Cr, quarter to Jun 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
Back to profit in the quarter to Jun 2026, ₹2.20 CrA loss in 7 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.28 | 6.28 | 4.83 | 1.94 | 2.53 | 4.33 | 3.31 | 8.22 |
| Net profit | −0.22 | −0.39 | −1.49 | −0.76 | −2.08 | −0.73 | −0.58 | 2.20 |
| Net margin | −2.3% | −6.3% | −31.0% | −39.4% | −82.1% | −16.9% | −17.6% | 26.8% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹12 Crdown 57.06%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹4.16 CrYear to Mar 2025: −₹2.09 Cr
- Net margin
- −34.3%
Revenue by year
Peak revenue ₹28 Cr, year to Mar 2025; lowest ₹0.06 Cr, year to Mar 2017
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 5 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.1 | 11.9 | 12.0 | 20.9 | 26.2 | 18.3 | 15.4 | 11.1 | 28.2 | 12.1 |
| Net profit | 0.0 | 0.0 | 0.1 | 0.4 | 0.8 | 0.1 | −0.1 | −5.8 | −2.1 | −4.2 |
| Net margin | −13.3% | 0.0% | 0.7% | 2.0% | 2.9% | 0.8% | −0.7% | −52.0% | −7.4% | −34.3% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, BULK DRUG AND DRUG INTERMEDIATES, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −32.7% | – | – | 0.0% |
| 3 years | −2.2% | – | – | 0.0% |
| 5 years | −4.3% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Promoter and insider buying and selling
Trades made since 31 Oct 2025.Parmax Pharma insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 14 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Parmax Pharma competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Parmax Pharma in market cap. Parmax Pharma's own figures are from its last trade, on 26 Oct 2026.Healthcare companies
Parmax Pharma is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Tyche IndustriesTYCHE | 102 | 22.81 | 0.72 | −21.0% | −63.5% | 3.2% | −2.5% | 3.53% |
 Pharmaids PharmaceuticalsPHARMAID | 98 | – | 2.05 | +18.5% | – | −8.5% | −15.8% | 0.00% |
 Veerhealth CareVEERHEALTH | 97 | 63.23 | 4.22 | +177.2% | +199.7% | 6.8% | 11.0% | 0.00% |
 Mercury LaboratoriesMERCURYLAB | 95 | 22.77 | 1.63 | −3.7% | +10.4% | 7.5% | 7.0% | 0.44% |
 Vaishali PharmaVAISHALI | 87 | 19.56 | 1.25 | – | – | 6.6% | 4.2% | 0.00% |
 Denis Chem LabDENISCHEM | 85 | 10.64 | 0.93 | +4.1% | −5.8% | 9.0% | 10.4% | 4.09% |
 Concord DrugsCONCORD | 84 | 40.81 | – | +82.5% | +380.5% | 5.0% | 7.1% | 0.00% |
 Cian HealthcareCHCL | 84 | – | 9.81 | −8.1% | – | −113.9% | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Parmax Pharma announcements
Oct 2026
28 Oct · Management
8 Oct · Management
1 Oct · Meeting
Sep 2026
29 Sep · Meeting
28 Sep · Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015 - Intimation Of Fire Incident At The Plant Of The Company
7 Sep · Meeting
Parmax Pharma annual Report of Financial Year 2025-26 along with Notice of Annual General Meeting
Parmax Pharma share price by year
Each calendar year to 2025.Parmax Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 33.83 | −23.5% | 48.94 | 29.67 |
| 2024 | 44.25 | +35.9% | 51.66 | 25.90 |
| 2023 | 32.57 | −15.8% | 39.35 | 27.55 |
| 2022 | 38.70 | −35.4% | 61.95 | 27.15 |
| 2021 | 59.95 | +103.2% | 78.00 | 24.25 |
| 2020 | 29.50 | +63.9% | 49.90 | 15.20 |
| 2019 | 18.00 | +4.0% | 19.00 | 17.30 |
| 2018 | 17.30 | +1.8% | 21.25 | 17.00 |
| 2017 | 17.00 | – | 17.00 | 12.50 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 18 Feb 2020. 2019 is from its first session, 23 Apr 2019. 2018 is from its first session, 27 Feb 2018. 2017 is from its first session, 17 Mar 2017. The close is the year's last trade for 2019 (5 Dec 2019) and 2018 (28 Nov 2018).
Recent sessions
The 9 trading days to 19 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 19 Oct 2026 | 136.40 | 136.40 | 136.40 | 136.40 | 136.40 | 271 |
| 12 Oct 2026 | 139.10 | 139.10 | 137.75 | 137.75 | 138.10 | 1,506 |
| 5 Oct 2026 | 137.75 | 139.10 | 136.40 | 139.10 | 138.03 | 12,921 |
| 28 Sep 2026 | 137.20 | 137.75 | 136.95 | 137.75 | 137.73 | 16,216 |
| 21 Sep 2026 | 136.40 | 136.40 | 136.40 | 136.40 | 136.40 | 3,917 |
| 15 Sep 2026 | 135.05 | 135.05 | 135.00 | 135.05 | 135.05 | 6,334 |
| 7 Sep 2026 | 133.75 | 133.75 | 133.75 | 133.75 | 133.75 | 2,018 |
| 31 Aug 2026 | 132.45 | 132.45 | 132.45 | 132.45 | 132.45 | 12,767 |
| 24 Aug 2026 | 131.15 | 131.15 | 131.15 | 131.15 | 131.15 | 54,997 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 540359
- ISIN
- INE240T01014
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.parmaxpharma.com
- CIN
- L24231GJ1994PLC023504
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1994
- Registered office
- Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, 360311, Gujarat
- Share registrar
- Purva Sharegistry (India) Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments